Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study
|
|
- Gertrude Newton
- 6 years ago
- Views:
Transcription
1 Tropical Medicine and International Health doi: /tmi volume 20 no 11 pp november 2015 Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study Xiulei Zhang 1, Jia Yin 2, Haitao Li 1, Shuguang Li 1, John Walley 3, Guanyang Zou 3, Zhitong Zhang 3 and Xiaolin Wei 2 1 Center for TB Control, Shandong Provincial Chest Hospital, Shandong, China 2 School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China 3 Nuffield Centre for International Health and Development, University of Leeds, Leeds, UK Abstract objective Shandong Province has implemented the standardised treatment of multidrug-resistant tuberculosis (MDR-TB) supported by the Global Fund. The study aimed to understand the managements and delays of patients with MDR-TB before initiating their treatments. methods All patients with MDR-TB who had completed intensive phase treatment from January 2010 to May 2012 were interviewed using a structured questionnaire. Delays and treatments were analysed. Diagnosis delay is defined as the period between having sputum smear results and drug susceptibility test (DST) results. Treatment delay was defined as starting MDR-TB treatment more than 2 days after receiving the diagnosis of MDR-TB. Total delay is the sum of diagnosis delay and treatment delay. results In total, 110 patients with MDR-TB participated in the study. Median delay for diagnosis was 102 days. Over 80% of patients had a diagnosis delay longer than 90 days. MDR-TB treatments commenced after a median of 9 days after DST results, and over 37% of the patients with MDR-TB experienced treatment delays. Chronic cases or patients with indifferent attitude had significantly longer treatment delay than other groups (P = 0.03 and 0.03, respectively). During their delays, of 44 patients with retreatment failures, 12 (27.3%) were treated through adding single second line drugs (SLDs) to first-line regimens, and 25 (56.8%) were treated with first-line drugs. A high proportion of initial treatment failure/relapsed/returned cases (37%) and new cases (43%) were administered with SLDs. conclusions Most of the patients with MDR-TB experienced prolonged diagnosis delay, which was the most important factor contributing to the total delay. Misuse of SLDs during the days was common, so necessary training should be given to prevent irrational prescription of medications. keywords multidrug-resistant tuberculosis, treatment delay, diagnosis delay, second-line drugs, China Introduction Multidrug-resistant tuberculosis (MDR-TB) is defined as tuberculosis strains resistant to at least isoniazid (INH) and rifampicin (RFP). MDR-TB poses a paramount threat to global TB control and incurs a huge burden to international community due to its difficult, expensive, less effective and toxic treatment. To diagnose MDR-TB, drug susceptibility tests (DSTs) need to be undertaken. World Health Organization (WHO) suggests that DST is routinely provided to all patients with TB or patients with high risk of drug resistance at the start of treatment [1]. In 2008, DST was performed in only 3% of previously treated cases in 27 countries with the highest burden of MDR-TB [2]. Solid culture and conventional DST take between 2 and 4 months or longer in most countries [3 5]. Delay of appropriate treatment contributes to the poor treatment outcome, further transmission and amplification of MDR-TB, while delayed treatment or inadequate treatment with a single secondline drug (SLD) also increase the risk of generating extensive drug resistance (XDR) [3, 6]. China carries the largest burden of MDR-TB and has the second highest number of TB cases in the world [7]. According to the national 2007 TB drug resistance survey in China, 5.7% of new smear-positive cases and 25.6% 2015 John Wiley & Sons Ltd 1431
2 of retreated cases were MDR-TB [8], and about new MDR-TB cases are estimated in China annually [8]. To improve MDR-TB control, a project supported by the Global Fund (GF) against HIV/AIDS, tuberculosis and malaria has been implemented in several provinces of China, including Shandong Province, since Shandong Province, located in eastern China with a population of 94 million, is divided into 17 prefectures and 140 counties. By 2005, directly observed treatment, short-course (DOTS) strategy had covered all counties and the detection rate of new smear-positive case has been more than 70% in Shandong Province. A basic DOTS unit, called TB dispensary, is located at the county level, providing free anti-tb treatment according to DOTS strategy [9]. Five prefectures have been implementing the GF project since 2010, which covers 44 counties with a total population of 33 million. TB dispensaries at the county level are responsible for collecting and delivering sputum samples of MDR-TB suspects to the laboratories of prefectural designated MDR-TB hospitals (DMH) for culture, which include chronic patients who experienced multiple treatment courses but remained smear positive, the relapsed/ returned patients, patients with initial treatment and retreatment failure, close contacts of MDR-TB cases and non-converted new cases by the end of the intensive treatment phase. DSTs are only available in the provincial reference laboratory, which are performed using conventional proportion method on solid media as recommended by the WHO [10]. DST results are sent back to DMH, and the project officer immediately informs patients with MDR-TB, via community health centres if necessary, and requests the patient for a clinical evaluation. DMH serves as the prefectural MDR-TB clinical management centre. The standard regimen of GF project is 6 months of intensive phase using amikacin, moxifloxacin, pyrazinamide, cycloserine (para-aminosalicylic acid) and protionamide and 18 months of continuous phase using moxifloxacin, pyrazinamide, cycloserine (para-aminosalicylic acid) and protionamide. Although WHO recommends GeneXpert method for its potential to decrease diagnosis delays [3], expanding GeneXpert at the facility level requires tremendous financial resources and capacity building that the middle- and low-income countries cannot afford to. Those who could not tolerate the standardised treatment regimens or needed individu- County TB dispensary Sputum samples MDR-TB suspects Pre-confirmation treatment Non-MDR-TB referred back for DOT Community DOT Culture Prefecture TB Hospital Positive Pre-confirmation treatment MDR-TB Hospitalization and follow-up management DST Provincial TB reference Lab MDR-TB Non-MDR-TB DST report Figure 1 Steps of multidrug-resistant tuberculosis diagnosis and treatment John Wiley & Sons Ltd
3 alised regimens were not recruited in the project. The procedures of diagnosis are illustrated in Figure 1. Regarding regimens given to patients during the diagnosis of MDR-TB, the China s MDR-TB management guideline suggests providing first-line anti-tb regimens to patients who are initial treatment failure/relapse/return cases and new cases, while empirical second-line anti-tb regimens should be given to those who are chronic/retreatment failures after clinical evaluation [11]. The management of MDR-TB has been extensively documented; however, little has been reported regarding management issues during the time from being suspected as MDR-TB to initiation of MDR-TB treatment. The study aimed to fill this gap and to provide recommendations for the future scale-up of programmatic management of MDR-TB. Methods We selected all patients with MDR-TB who were registered from 2010 and had completed more than 6 months of intensive treatment in May Medical records of all these patients regarding their treatment during the MDR-TB diagnostic period were collected and reviewed. Face-to-face interviews were conducted for all these patients using a structured questionnaire about their knowledge and perceptions regarding TB, care-seeking process and treatments before they were formally enrolled into MDR-TB treatment. In this study, the definitions of patient categories are in line with WHO guideline for treatment of tuberculosis [2]. Diagnosis delay was defined as the period between the time when sputum smear results were available and the time when DST results were available. Treatment delay was defined as starting MDR-TB treatment more than 2 days after receiving the diagnosis of MDR-TB. Differences in proportions were tested using Pearson s chi-square test. Ninety-five per cent confidence intervals (95% CI) were calculated using the exact binomial method. All tests were two-sided, and a threshold of P = 0.05 was used to define statistical significance. Factors associated with treatment delay including age, sex, education, treatment category and patients perceptions were tested. Ethical clearance for this study was sought from the Ethics Committees of the Shandong Provincial Chest Hospital, China. Written informed consents were obtained from participants when they agreed to attend this study. Results In the five prefectures, 119 cases had finished 6 months of treatment, of whom, 110 (92.4%) were interviewed. Nine patients who were too weak, not available at the time, or already defaulted from the treatment did not participate in the interview. Among 110 patients, 81 (73.6%) were males and 29 (26.4%) were females. Most of whom had not attended high school education. Farmers accounted for 50%. Among 110 patients, 21 (18%) were new cases, and 89 (80.9%) were retreated cases. Of whom, 44 (49.4%) were retreatment failure. Diagnosis delay Most of the cases (81%) had a diagnosis time longer than 90 days, and 19% of the cases had a diagnosis time longer than 180 days. The median diagnosis delay was 102 days. The median interval between the time when sputum was sent for culture and the time when culture result was available was 44.5 days, while the median interval was of 66 days between the time when strains were sent for DST and the time when DST results were received (Table 1). Treatment delay and risk factors Over 37% of the 110 cases had treatment delay, with a median interval of 9 days. The median total delay, that is the diagnostic delay plus treatment delay, was 120 days Table 1 Time interval breakdown of delays Time interval (day) Mean Median 25th percentile 75th percentile Days of diagnosis delay Time between sputum result available and sputum sample sent for culture Time between sputum sample received for culture and culture result available Time between culture result available and samples sent for DST Time between samples sent for DST and DST result received Days of treatment delay Total delay John Wiley & Sons Ltd 1433
4 (Table 1). Sex, age, education, profession and previous treatment expenditures were not significantly associated with treatment delay. However, chronic cases who had experienced multiple treatment courses were more likely to have treatment delay (P = 0.033), and patients who did not appreciate the seriousness of TB tended to have treatment delay (P = 0.028; Table 2). drugs. A total of 36.8% of initial treatment failure/relapse/return cases (14/38) and 42.9% of new cases (9/21) were administered with SLDs. The most frequently used SLDs were fluoroquinolones (80%) including ofloxacin or levofloxacin, which was followed by injectable aminoglycoside (20%), mainly amikacin. Misuse of SLDs mostly happened in the specialised TB hospitals. Use of second-line TB drugs While waiting for DST results, patients were treated at the specialised TB hospitals, county TB dispensaries and private health facilities. Patients categories, treatment principle for each category, the number and percentage of patients using SLDs, and facilities using SLDs to treat patients while waiting for DST results are illustrated in Table 3. Of 44 patients with retreatment failures, 12 (27.3%) were treated through adding single SLDs to firstline regimens, and 25 (56.8%) were treated with first-line Discussion WHO recommends that one laboratory for sputum culture and DST should be established in every five million population [12]. However, the capacity of laboratory to detect anti-tb drug resistance is still low in China. In this study, an area covering 33 million in Shandong did not have the DST capacity but had to rely on the provincial reference laboratory, which may have contributed to the severe diagnosis and treatment delays of patients with TB. Table 2 Treatment delay and its contributing risk factors of the Multidrug-resistant tuberculosis patients in Shandong, China 2 days >2 days P OR 95% CI Factors No. No. (%) No. (%) Category New cases (57.1) 9 (42.9) (0.011, 1.033) Relapsed (70.8) 7 (29.2) (0.006, 0.571) Initial treatment failure (76.9) 3 (23.1) (0.004, 0.502) Retreatment failure (65.9) 15 (34.1) (0.008, 0.658) Chronicle cases 8 1 (12.5) 7 (87.5) 1 Perceptions to TB TB is a serious disease (65.9) 33 (34.1) (0.072, 0.920) TB is not a serious disease 12 4 (33.3) 8 (66.7) 1 Table 3 Treatment before confirming multidrug-resistant tuberculosis status Cases used second-line anti-tb drugs (%) Different health facilities administered second-line anti-tb drugs (No. of case and proportion) Category of patients Principle of treatment before confirming MDR-TB No. of cases Total Added single drugs Added multiple drugs Specialised TB hospital County TB dispensary Private facilities Retreatment failure/ chronic cases Initial treatment failure/relapsed/ return Existing treatment or empirical MDR-TB treatment (27.3) 7 (15.9) 15 (78.9) 3 (15.8) 1 (5.3) Retreatment (26.3) 4 (10.5) 12 (85.7) 2 (14.3) 0 New cases Initial treatment (38.1) 1 (4.8) 6 (66.7) 3 (33.3) 0 Others Empirical treatment (28.6) 0 2 (100) 0 0 Total (29) 12 (10.9) 35 (79.5) 8 (18.2) 1 (2.3) John Wiley & Sons Ltd
5 According to China s MDR-TB management guideline, results of conventional DST should be read within 4 weeks of inoculation [11]. In our study, it took 66 days in median to wait for results after receiving samples for DST. The total delay was 4 months in our study, which was worse than findings of two studies in South Africa. Where a mean delay of 12.4 weeks from the date of sputum collection for culture and DST to the start of treatment [13], and an average of 5 6 weeks delay using traditional culture methods were reported [14]. The longer delay in Shandong Province was mostly due to the limited capacity of laboratories at the prefectural level, because samples had to be sent to the provincial laboratory for DST and where the amount of samples often exceeded its handling capacity. Process of sample delivering and feedback of DST results could have taken less time if county-level TB dispensary, prefecture-level DMH and provincial reference laboratory had better coordination in place. However, more importantly, DMH laboratories should be responsible for DST of their respective prefectures at the earliest occasion and be equipped with necessary devices, trained technicians and infection control facilities, which will significantly reduce the DST time. Application of rapid DST techniques, including providing finances and reagent supplies, may be useful to reduce diagnostic delays and expedite treatment for drug-resistant TB, but the methods should be piloted before wide application [15]. GeneXpert MTB/RIF, line probe assays and Genechip are being evaluated by China s National Reference Laboratory, but are yet to be incorporated into the current diagnostic algorithms. Besides the evaluation of these methods, the high initial costs and the recurrent costs for most rapid tests, and related capacity building and facility costs should also be addressed before scaleup [16]. Bactec-MGIT 960 is being used in some hospitals. However, due to its high cost of equipment and reagents, over 10 days of turnaround time and promise of GeneXpert MTB/RIF, many TB hospitals in China hesitate to introduce the technology. We observed a profoundly long delay in initiating anti- MDR-TB treatment, which may increase the possibility of transmitting the disease to the general population [17]. Unlike Chen s study on drug-susceptible TB, this study showed that financial burden did not prevent patients with MDR-TB from seeking MDR-TB treatment probably because the GF project provided a comprehensive free treatment and care package [18]. Chronic cases and those who did not regard TB as a serious disease were more likely to have treatment delay. Irrational regimens, substandard drugs, insufficient dosage and inadequate treatment period and inappropriate drug administration have contributed to the development of drug resistance [19]. China s guidelines require that empirical MDR regimen be given to patients of retreatment failures before drug resistance profile is confirmed to reduce treatment delay [11]. Empirical MDR- TB treatment consists of at least four drugs with the certain effects based on their treatment histories [2]. Clearly, this study revealed that the guidelines were not properly followed; for example, some retreatment failure cases were not put on empirical MDR-TB treatment, but were treated by adding single drugs to first-line anti-tb regimens. Furthermore, more than 39% of the patients with MDR-TB, who were initial treatment failure/relapse/return cases or new cases, were treated with second-line anti-tb drugs, which is against the national guidelines. Another striking fact was the inadequately formulated regimens mainly occurred at specialised TB hospitals. One possible reason for misusing SLDs may be that health facilities induce demand on irrational use of SLDs to generate revenues from treating patients [20]. Previous studies also established that specialist hospitals had mismanaged drug-susceptible TB cases compared with TB dispensaries [21, 22]. The addition of one single second-line drug would increase the risk of generating XDR-TB. A study by [23] showed that there is poor administration of drugs in health facilities in China, where some second-line drugs, such as fluoroquinolone, are easily and extensively prescribed for respiratory infections and other bacterial infections and in some cases even available without a prescription in local drug stores. In addition, easy access and inappropriate use of these drugs increase the risk for the emergence of drug resistance [24]. Worth to mention is that some of Chinese guidelines recommendations are questionable and may need further emendation in the future. For example, giving retreatment regimen to an initial treatment failure without obtaining DST results is debatable. As WHO recommends that DST should be given to all previously treated patients with TB at or before the start of treatment, patients whose prior course of therapy has failed should therefore receive an empirical MDR regimen [2]. However, DST is not yet routinely available in Shandong and most of China. WHO recommends using the empirical regimens should continue throughout the course of treatment. Unreasonable treatment regimens is one of the important reasons that produces MDR-TB [25]. The study was a retrospective investigation, and patients may not recall all the details correctly. As part of large study examining treatment issues before MDR- TB diagnosis and after diagnosis [26], only patients who had competed 6 months of intensive treatment in the GF project were included, so selection bias exists in the 2015 John Wiley & Sons Ltd 1435
6 study. Patients who were not included in the GF project did not receive the financial support and may experience more severe delays; thus, the study may have underestimated patient delays in normal conditions. Shandong is a province with very low prevalence of HIV/AIDS, so we did not include information about these patients HIV status. Conclusion We found that most patients experienced prolonged diagnosis delay in MDR-TB treatment. Rapid DST techniques should be introduced at the prefectural MDR-TB centres. Sample transportation and information exchange need to be further streamlined. Patients who had chronic TB or did not appreciate the seriousness of TB treatment tended to have treatment delay. Misuse of SLDs was common, and so necessary training should be introduced to prevent irrational prescription of medications. Acknowledgements The study was funded and proved by COMDIS Health Service Delivery Research Programme Consortium (COMDIS HSD), a six-year programme ( ) funded by the UK Department for International Development. COMDIS HSD did not play a role in the collection, analysis, interpretation of data and in the decision to submit the manuscript for publication. We also thank Robinah Najjemba of Department of Essential of Medicine, World Health Organization who proofread the manuscript. References 1. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization: Geneva, Switzerland, 2008b. 2. World Health Organization. Guidelines for Treatment of Tuberculosis (4th edn), World Health Organization: Geneva, Albert H, Bwanga F, Mukkada S, et al. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis 2010: 10: Shen X, DeRiemer K, Yuan ZA, et al. Drug-resistant tuberculosis in Shanghai, China, : prevalence, trends and risk factors. Int J Tuberculosis Lung Dis 2009: 13: Zhao M, Li X, Xu P, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE 2009: 4: e Velasquez GE, Yagui M, Cegielski JP, et al. Targeted drugresistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, Emerg Infect Dis 2011: 17: World Health Organization. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB):2010 Global Report on Surveillance and Response. World Health Organization: Geneva, China s Ministry of Health. Report of National TB Drug Resistance Survey ( ). People s Health Press: Beijing, China s Ministry of Health. Guidelines for Implementing the National Tuberculosis Control Program in China (2008). Peking Union Medical College Press: Beijing, World Health Organization. Anti-Tuberculosis Drug Resistance in the World. World Health Organization: Geneva, 2008a. 11. Wang Y. Multi-Drug Resistant Tuberculosis Control and Management Guideline. Military Medical Science Press: Beijing, World Health Organization. Global Tuberculosis Control Report. World Health Organization: Geneva, Narasimooloo R, Ross A. Delay in commencing treatment for MDR TB at a specialised TB treatment centre in Kwa- Zulu-Natal. S Afr Med J 2012: 102: Bamford C, Taljaard J. Potential for nosocomial transmission of multidrug-resistant tuberculosis (MDR TB) in a South African hospital. S Afr Med J 2010: 100: Gler MT, Guilatco RS, Guray CV. Screening outcomes form patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines. Int J Tuberc Lung Dis 2012: 16: Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010: 14: Yagui M, Perales MT, Asencios L, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis 2006: 10: Chen Q, Zheng J, Wu N. Analysis on the correlated factors of delay in tuberculosis diagnosis and treatment in Fujian province. Chin J Anti-Tuberculosis Assoc 2005: 27: Liang L, Wu Q, Gao L, et al. Factors contributing to the high prevalence of muntidrug-resistant tuberculosis: a study from China. Thorax 2012: 67: Meng Q, Li R, Cheng G, Blas E. Provision and financial burden of TB services in a financially decentralized system: a case study from Shandong, China. Int J Health Plan Manage 2004: 19: s45 s Wei X, Zou G, Walley J, et al. China tuberculosis policy at crucial crossroads: comparing the practice of different hospital and tuberculosis control collaboration models using survey data. PLoS ONE 2014: 9: e Wei X, Zou G, Yin J, Walley J, Sun Q. Comparing patient care seeking pathways in three models of hospital and TB programme collaboration in China. BMC Infect Dis 2013: 13: John Wiley & Sons Ltd
7 23. Hu Y, Hoffner S, Wu L, Zhao Q, Jiang W, Xu B. Prevalence and genetic characterization of second-line drug- resistant and extensively drug-resistant Mycobacterium tuberculosis in rural China. Antimicrob Agents Chemother 2013: 57: Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med 2009: 150: Espinal M, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001: 5: Wei X-L, Yin J, Zou G-Y, et al. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. Int J Tuberc Lung Dis 2015: 19: Corresponding Author Xiaolin Wei, School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China. Tel.: ; Fax ; xiaolinwei@cuhk.edu.hk 2015 John Wiley & Sons Ltd 1437
MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationMultidrug-Resistant TB
Multidrug-Resistant TB Diagnosis Treatment Linking Diagnosis and Treatment Charles L. Daley, M.D. National Jewish Health University of Colorado Denver Disclosures Chair, Data Monitoring Committee for delamanid
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationArticles. Funding Bill & Melinda Gates Foundation. Copyright Li et al. Open Access article distributed under the terms of CC BY-NC-ND.
Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrugresistant tuberculosis in China: a before-and-after study Renzhong Li*, Yunzhou Ruan*, Qiang Sun*,
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationXpert MTB/RIF assay validation experience --- impact and plan in China
Xpert MTB/RIF assay validation experience --- impact and plan in China Dr. Zhao Yanlin Chinese Center for Disease Control & Prevention Dr. Richard O Brien FIND April. 16, 2013 Progress Contribution for
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationDRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION
JOURNAL OF PREVENTIVE MEDICINE 2008; 16(3-4): 3-9 Inviting Editorial DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION Harshad Thakur Centre for Health Policy, Planning and Management,
More informationManagement of Drug-resistant Tuberculosis (DR-TB)
Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical
More informationOnline Annexes (5-8)
Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationOnline Annexes (5-8)
2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings
More informationTransmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University
Transmission of MDR/XDR Tuberculosis in Shanghai Qian Gao Shanghai Medical College Fudan University Drug Resistant TB in China The Highest DR-TB Burden Country New TB cases/year Cases with any DR MDR XDR
More informationTitle: Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas in China
Author's response to reviews Title: Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas in China Authors: Song Yao (ys506506@yahoo.com.cn) Wen-Hui Huang
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationPrevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, China
Li et al. Antimicrobial Resistance and Infection Control (2018) 7:61 https://doi.org/10.1186/s13756-018-0348-7 RESEARCH Open Access Prevalence and patterns of drug resistance among pulmonary tuberculosis
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationManagement of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building
Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention
More informationPrevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011
Original Research Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Hoa Binh Nguyen, ab Nhung Viet Nguyen, ac Huong Thi Giang Tran,
More informationRole of RNTCP in the management MDR-TB
Kamdar DJ, Shah NA, Patel DJ, Parmarr H. Role of RNTCP in the management of MDR-TB. IAIM, 2015; 2(7): 1-5. Original Research Article Role of RNTCP in the management of MDR-TB Deepali J Kamdar 1, Neha A
More informationChanges in pulmonary tuberculosis prevalence: evidence from the 2010 population survey in a populous province of China
Wei et al. BMC Infectious Diseases 2014, 14:21 RESEARCH ARTICLE Open Access Changes in pulmonary tuberculosis prevalence: evidence from the 2010 population survey in a populous province of China Xiaolin
More informationOriginal Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
Int J Clin Exp Pathol 2017;10(4):4847-4851 www.ijcep.com /ISSN:1936-2625/IJCEP0045802 Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
More informationMultidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017
Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationPrinciple of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos
Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases
More informationNational Survey of Drug-Resistant Tuberculosis in China Dr. Yanlin Zhao
National Survey of Drug-Resistant Tuberculosis in China Dr. Yanlin Zhao National Centre for Tuberculosis Control and Prevention of China CDC National TB Reference Laboratory, China CDC BACKGROUND China
More informationHIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationFeasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru Pedro G Suárez, Katherine Floyd, Jaime Portocarrero, Edith
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes
More informationEpidemiology of drug-resistant tuberculosis among children and adolescents in South Africa
Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa 2005 2010 BK Moore 1, E Anyalechi 1, M van der Walt 2, S Smith 1, L Erasmus 3, J Lancaster 2, S Morris 1, N Ndjeka
More informationNational Survey of Drug-Resistant Tuberculosis in China
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article National Survey of Drug-Resistant Tuberculosis in China Yanlin Zhao, Ph.D., Shaofa Xu, M.D., Lixia Wang, M.S., Daniel P. Chin, M.D.,
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
More informationThe epidemiology of tuberculosis
The epidemiology of tuberculosis Tuberculosis Workshop Shanghai, 12-22 May 28 Philippe Glaziou World Health Organization Outline Epidemiology refresher Estimates of tuberculosis disease burden Notifications
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationTUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report
TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION 2000 Tuberculosis Control In the WHO Western Pacific Region 2002 Report World Health Organization Office for the Western Pacific Region iii TUBERCULOSIS
More informationMortality and associated factors of patients with extensive drug-resistant tuberculosis: an emerging public health crisis in China
Bei et al. BMC Infectious Diseases (2018) 18:261 https://doi.org/10.1186/s12879-018-3169-7 RESEARCH ARTICLE Open Access Mortality and associated factors of patients with extensive drug-resistant tuberculosis:
More informationMultidrug-resistant TB in Zambia: review of national data from 2000 to 2011
Tropical Medicine and International Health doi:10.1111/tmi.12183 volume 00 no 00 Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011 Nathan Kapata 1,2,3,5, Pascalina Chanda-Kapata
More informationIncreasing access to the MDR-TB surveillance programme through a collaborative model in western Kenya*
Tropical Medicine and International Health doi:10.1111/j.1365-3156.2011.02933.x volume 17 no 3 pp 374 379 march 2012 Increasing access to the MDR-TB surveillance programme through a collaborative model
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationXDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationKenya Perspectives. Post-2015 Development Agenda. Tuberculosis
Kenya Perspectives Post-2015 Development Agenda Tuberculosis SPEAKERS Anna Vassall Anna Vassall is Senior Lecturer in Health Economics at the London School of Hygiene and Tropical Medicine. She is a health
More informationAuthor s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Authors: Phan Thai (phanvuongkhacthai@yahoo.com) Dang Ha
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationQian Gao Fudan University
Qian Gao Fudan University Outline Background & Objectives Genotyping methods Establish the epidemiological field sites Preliminary results of Molecular epidemiology of TB in China Molecular epidemiology
More information2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:
The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.
More informationModern TB Diagnostic Services: Optimizing the Old with the New
Modern TB Diagnostic Services: Optimizing the Old with the New 6 th Global Laboratory Initiative (GLI) Partners Meeting incorporating Global consultation of the TB SRL Network Global Forum of Xpert MTB/RIF
More informationControlling TB in the era of HIV
Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population
More informationMultidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Multi-Ethnic Region, Xinjiang Uygur Autonomous Region, China
Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Multi-Ethnic Region, Xinjiang Uygur Autonomous Region, China Ying-Cheng Qi 1., Mai-Juan Ma 2., Dong-Jun Li 3, Mei-Juan Chen 1, Qing-Bin
More informationWhat can be done against XDR-TB?
What can be done against XDR-TB? Dr Matteo Zignol Stop TB Dep. World Health Organization Geneva 16 th Swiss Symposium on tuberculosis Münchenwiler, 22 March 2007 XDR-TB Extensive Drug Resistance XDR =
More informationAnnex 1. Methods for evidence reviews and modelling
WHO/HTM/TB/2011.6a. Methods for evidence reviews and modelling Questions for the 2011 update of the Guidelines for the programmatic management of drug-resistant tuberculosis (for Outcomes please see Table
More informationMultidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area
Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)
More informationOsaka City is the third largest city (population
Surveillance Report Strengthened tuberculosis control programme and trend of multidrug resistant tuberculosis rate in Osaka City, Japan Akira Shimouchi, a Akihiro Ohkado, a Kenji Matsumoto, b Jun Komukai,
More informationQuestions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs
Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationEffectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) M Bonnet, M Bastard, P du Cros, K Atadjan, K Kimenye, S Khurkhumal, A Hayrapetyan, A Telnov, C Hewison, F Varaine
More informationEffectiveness of DOTS regime in terms of cure, failure, default and relapse in the treatment of TB patients
International Journal of Advances in Medicine Jahnavi K et al. Int J Adv Med. 2018 Feb;5(1):170-174 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20180079
More informationGuidelines for TB contact tracing in Pacific Island countries and territories
Guidelines for TB contact tracing in Pacific Island countries and territories Background Tuberculosis (TB) continues to be a public health issue of major significance around the world. The World Health
More informationThe emerging threat of multidrug resistant TB: Global and local challenges and solutions
Summary of IOM-ASSAf Workshop on: The emerging threat of multidrug resistant TB: Global and local challenges and solutions Salim S. Abdool Karim Pretoria - March, 2010 Why this workshop? Why is it on MDR
More informationScott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer
Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of
More informationProcurement update: StopTB Partnership - Global Drug Facility (GDF)
Procurement update: StopTB Partnership - Global Drug Facility (GDF) Magali BABALEY Strategic Procurement and Business Intelligence Manager Stop TB Partnership, Global Drug Facility (GDF) team joint UNICEF-UNFPA-WHO
More informationOverview: TB Alliance Drug Development Pipeline
Overview: TB Alliance Drug Development Pipeline Mengchun Li, MD Head of Pharmacovigilance, TB Alliance Mar 26, 2018 TB Alliance is a not for profit organization dedicated to the discovery and development
More informationXpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10 Introduction Excellent performances, rapid results, and easy to use Questions Where and how are we going
More informationA review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa
A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa *Castelnuovo B Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda Abstract
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 5, Issue 2 Newsletter Date: February 2013 APSR EDUCATION PUBLICATION Inside this issue: Tuberculosis Multidrug-resistant pulmonary tuberculosis treatment regimens and patient
More informationTreatment outcomes and survival based on drug resistance patterns in multidrug-resistant
Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis Doh Hyung Kim, Hee Jin Kim, Seung-Kyu Park, Suck-Jun Kong, Young Sam Kim, Tae-Hyung Kim, Eun Kyung
More informationMycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline
Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana
More informationPredictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Eur Respir J 2009; 33: 1085 1094 DOI: 10.1183/09031936.00155708 CopyrightßERS Journals Ltd 2009 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB K. Kliiman and
More informationRamesh P. M.*, Saravanan M.
International Journal of Advances in Medicine Ramesh PM et al. Int J Adv Med. 2018 Jun;5(3):561-565 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20181663
More informationThe WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps
The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps Matteo Zignol STOP TB Department World Health Organization TB surveillance and
More informationApplication of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes
Application of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes Dr Amal Bassili Stop TB unit, WHO, Regional Office for the Eastern Mediterranean Surveillance
More informationTotally Drug-Resistant Tuberculosis (TDR-TB): An Overview
Human Journals Review Article August 2016 Vol.:1, Issue:3 All rights are reserved by Mr. Suraj Narayan Mali et al. Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Keywords: Totally Drug-resistant
More informationWHERE DO WE GO FROM HERE?
WHERE DO WE GO FROM HERE? WHAT WILL BE REQUIRED TO ACHIEVE ZERO DEATHS FROM TUBERCULOSIS? SALMAAN KESHAVJEE, MD, PHD, SCM HARVARD MEDICAL SCHOOL BRIGHAM AND WOMEN S HOSPITAL PARTNERS IN HEALTH INTERNATIONAL
More informationNew Frontiers: Innovation and Access
8 th Regional TB Symposium - Tashkent, Uzbekistan New Frontiers: Innovation and Access New Guidelines: An Opportunity for National Programmes and Patients: Evidence for new WHO recommendations on MDR-TB
More informationDrug-resistant Tuberculosis
page 1/6 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Context - Tuberculosis (TB) is an infectious disease that affects a growing number of
More informationFinding the missing TB cases
Finding the missing TB cases Optimizing strategies to enhance case detection in high HIV burden settings Dr Malgosia Grzemska Global TB Programme, WHO/HQ, Geneva SWITZERLAND Child and Adolescent TB Working
More informationTuberculosis among public sector healthcare workers in ethekwini District, KwaZulu-Natal
ORIGINAL RESEARCH Tuberculosis among public sector healthcare workers in ethekwini District, KwaZulu-Natal S Mahomed 1, DR Khilawan 2, S Knight 2 1 School of Laboratory Medicine and Medical Science, College
More informationPredicting outcomes and drug resistance with standardised treatment of active tuberculosis
Eur Respir J 21; 36: 87 877 DOI: 1.1183/931936.15179 CopyrightßERS 21 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis O. Oxlade*,#, K. Schwartzman*,#, M. Pai*,#,
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationInternational Journal of Sciences: Basic and Applied Research (IJSBAR) ISSN (Print & Online)
International Journal of Sciences: Basic and Applied Research (IJSBAR) ISSN 2307-4531 (Print & Online) http://gssrr.org/index.php?journal=journalofbasicandapplied ---------------------------------------------------------------------------------------------------------------------------
More informationAnnex 2. GRADE glossary and summary of evidence tables
WHO/HTM/TB/2011.6b. GRADE glossary and summary of evidence tables GRADE glossary Absolute effect The absolute measure of intervention effects is the difference between the baseline risk of an outcome (for
More informationThe Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya
The Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya March 2017 Photo Credit: Francis Nsanga UHMG, Photoshare, Kenya RESEARCH SUMMARY A key element
More informationTUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND
Southeast Asian J Trop Med Public Health TUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND Piyada Kunawararak 1, Sathirakorn Pongpanich 2, Sakarin Chantawong 1, Pattana
More informationAvailable online at ScienceDirect. Procedia Environmental Sciences 36 (2016 ) 12 19
Available online at www.sciencedirect.com ScienceDirect Procedia Environmental Sciences 36 (2016 ) 12 19 International Conference on Geographies of Health and Living in Cities: Making Cities Healthy for
More informationThe Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public Hospital in Busan
Korean J Fam Med. 2012;33:372-380 http://dx.doi.org/10.4082/kjfm.2012.33.6.372 The Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public
More informationStrengthening and aligning diagnosis and treatment of drug-resistant TB in Russian Federation
LOGO Strengthening and aligning diagnosis and treatment of drug-resistant TB in Russian Federation Irina A.Vasilyeva Chief TB Specialist of the Russian Ministry of Health Central TB Research Institute,
More information: uptake and impact of Xpert MTB/RIF
Photo: Riccardo Venturi 21-215: uptake and impact of Xpert MTB/RIF Wayne van Gemert WHO Global TB Programme, Geneva Joint Partners Forum for Strengthening and Aligning TB Diagnosis and Treatment 27-3 April
More informationThe shorter regimen for MDR-TB: evidence and pitfalls
The shorter regimen for MDR-TB: evidence and pitfalls Helen Cox 10 November 2017 What is the shortened regimen? Current conventional regimen (SA): Intensive Phase (at least 6 months): PZA / (EMB) / Kana
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationKristina Wallengren, PhD MPH
Kristina Wallengren, PhD MPH Head of Clinical Research K-RITH South Africa K-RITH S AIM: TO CONDUCT EXCELLENT BASIC SCIENCE IN TB AND HIV XDR TB outbreak in Tugela Ferry, KwaZulu-Natal, 2005 XDR TB PREVALENCE
More informationCosting of the Sierra Leone National Strategic Plan for TB
Costing of the Sierra Leone National Strategic Plan for TB 2016-2020 Introduction The Government of Sierra Leone established the National Leprosy Control Programme in 1973 with support from the German
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationTB infection control: overview and importance
TB infection control: overview and importance John Ferguson, Newcastle, NSW Infectious Diseases & Microbiology jferguson@hnehealth.nsw.gov.au Goroka Hospital, September 2014 Patterns of TB disease Latent
More informationSirturo: a new treatment against multidrug resistant tuberculosis
Sirturo: a new treatment against multidrug resistant tuberculosis TB is an on-going problem WHO estimated incidence of new TB cases 2009 Global Tuberculosis Control: WHO report 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html
More information